In 2024, medication including both corticosteroids and biologics accounts for over 54% of U.S. market revenue, far surpassing surgical interventions https://www.einpresswire.com/article/834621980/u-s-nasal-polyps-treatment-market-strengthens-with-biologics-recent-trials-datam-intelligence